What Are You Looking For?
Founded in
Global Sites
Global Footprints
Patents & Certs
We provide a complete portfolio of patient-centered solutions for the diagnosis and management of reflux disease, supporting both clinical professionals and patient care.
VIEW ALL PRODUCTS
Pepfast is a non-invasive saliva test for reflux detection without centrifugation, results in 15 mins for convenient self-monitoring.
Peptest is a UK-origin, lab-based test that detects pepsin in saliva. Non-invasive and clinically validated—trusted by specialists worldwide.
Gasrelief is an oral medication that forms a gel barrier to physically block acid reflux. Starts working in 3 minutes, lasts up to 4 hours.
Maxhealth Innovative Meditech (Wuxi) LtdMei'an Innovative Medical Technology Wuxi Co., Ltd. has established a strategic partnership with RD Biomed, a UK-based company (Mei'an Holding's overseas R&D institution), and successfully developed the Peptest pepsin detection kit (colloidal gold method).
Explore the evolving world of reflux care. This section curates relevant industry trends, the latest clinical research, and updates on GERD management. We filter the news to provide insights that matter to healthcare professionals and patients alike, supporting informed decisions in gastrointestinal health.
Stay updated with Maxhealth Innovative Meditech. This section covers our latest company milestones, product developments, and global engagements. We share our journey of advancing digestive health through innovation.
Peptest, a groundbreaking non-invasive diagnostic tool for reflux disease, has officially entered the Chinese market after receiving medical device registration from the National Medical Products Administration (NMPA). This launch coincides with the release of China's first multidisciplinary expert...
Pepfast, our rapid and non‑invasive reflux test, has been commercialized in Hong Kong through a partnership with The HomeCare Medical Limited. The product received NMPA registration in May 2025 and was launched immediately. By July 2025, it had already entered the Hong Kong market through this coll...
Pepfast, our second‑generation, non‑invasive reflux diagnostic test, received NMPA registration in China in May 2025. Just seven months later, in December 2025, the product secured both CE marking and FDA clearance—enabling access to markets across Europe and the United States. Pepfast...
A comprehensive suite of reflux management solutions attracted significant attention from a global medical audience at a major healthcare exhibition in Thailand. The products were presented by a joint team of R&D engineers from RD Biomed Ltd (UK) and Maxhealth Innovative Meditech, engaging with...
Copyright @ 2026 Maxhealth Innovative Meditech (Wuxi) Ltd All Rights Reserved. 
Network Supported
Leave A Message
